FUS-immunoreactive intranuclear inclusions in neurodegenerative disease.
about
Molecular Pathological Classification of Neurodegenerative Diseases: Turning towards Precision MedicineFUS-mediated regulation of alternative RNA processing in neurons: insights from global transcriptome analysisA loss of FUS/TLS function leads to impaired cellular proliferationAdult-onset neuronal intranuclear hyaline inclusion disease is not rare in older adults.Gene expression responses to FUS, EWS, and TAF15 reduction and stress granule sequestration analyses identifies FET-protein non-redundant functions.RRM domain of ALS/FTD-causing FUS characteristic of irreversible unfolding spontaneously self-assembles into amyloid fibrils.Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLSFUS immunogold labeling TEM analysis of the neuronal cytoplasmic inclusions of neuronal intermediate filament inclusion disease: a frontotemporal lobar degeneration with FUS proteinopathy.FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration.FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations.The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease.Knockdown of the Drosophila fused in sarcoma (FUS) homologue causes deficient locomotive behavior and shortening of motoneuron terminal branches.Amyotrophic lateral sclerosis: update and new developments.Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs.FUS/TLS forms cytoplasmic aggregates, inhibits cell growth and interacts with TDP-43 in a yeast model of amyotrophic lateral sclerosis.Lentiviral vector-mediated overexpression of mutant ataxin-7 recapitulates SCA7 pathology and promotes accumulation of the FUS/TLS and MBNL1 RNA-binding proteinsRNA-mediated toxicity in neurodegenerative diseaseFUS/TLS acts as an aggregation-dependent modifier of polyglutamine disease model mice.FUS Mislocalization and Vulnerability to DNA Damage in ALS Patients Derived hiPSCs and Aging Motoneurons.TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration.RNA-binding proteins with prion-like domains in ALS and FTLD-U.Stress granules in neurodegeneration--lessons learnt from TAR DNA binding protein of 43 kDa and fused in sarcoma.The role of FUS gene variants in neurodegenerative diseases.Worming forward: amyotrophic lateral sclerosis toxicity mechanisms and genetic interactions in Caenorhabditis elegans.Aggregation of FET Proteins as a Pathological Change in Amyotrophic Lateral Sclerosis.The seeds of neurodegeneration: prion-like spreading in ALSMotoneuron Disease: Basic Science.Intracellular localization and splicing regulation of FUS/TLS are variably affected by amyotrophic lateral sclerosis-linked mutations.FUS/TLS deficiency causes behavioral and pathological abnormalities distinct from amyotrophic lateral sclerosis.Deciphering genetic interactions between ALS genes using C. elegans.Genetic mutations in RNA-binding proteins and their roles in ALS.Expression of human FUS/TLS in yeast leads to protein aggregation and cytotoxicity, recapitulating key features of FUS proteinopathy.ALS-associated protein FIG4 is localized in Pick and Lewy bodies, and also neuronal nuclear inclusions, in polyglutamine and intranuclear inclusion body diseases.Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations.Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series.FUS colocalizes with polyglutamine, but not with TDP-43 in neuronal intranuclear inclusions in spinocerebellar ataxia type 2.Presenile onset of spinocerebellar ataxia type 1 presenting with conspicuous psychiatric symptoms and widespread anti-expanded polyglutamine antibody- and fused in sarcoma antibody-immunopositive pathology.Atypical sporadic CJD-MM phenotype with white matter kuru plaques associated with intranuclear inclusion body and argyrophilic grain disease.Ubiquitin-related proteins in neuronal and glial intranuclear inclusions in intranuclear inclusion body disease.Fronto-temporal lobar degeneration: neuropathology in 60 cases.
P2860
Q26768648-70680DBF-2FD5-4E8C-AF31-04ACDCABE707Q26773038-1386C666-A903-4AE2-BBA5-647631915037Q27331026-46494F64-6A3B-4860-BBE2-5E65307A4D4DQ31063873-5EA9DA33-C643-49C8-B6CD-24943731DF15Q31104690-DE094BFB-F08E-4DF1-B0E4-F8417C80F430Q33683022-BF4D7FCE-7B54-4AC8-8D85-66C7C97765B0Q33889532-229F40E0-C74C-43A6-93EF-A0BA0141DC13Q33908722-8C397866-5911-4BD8-B24D-1234443C90A7Q33922335-F92EE0C5-7192-497C-82D3-7E1F02D96524Q34209561-795788D6-8480-4ABD-B097-34DC0134424BQ34263380-FFA8827C-8EEF-4390-8CC5-395980117435Q34314477-6251652F-AB5D-4F93-B50F-4FE3369C6405Q36278310-F28AE954-B010-40C2-A33E-039D063773CFQ36650975-7E1C2A2C-63D3-4F60-83AA-8E6C15FF67D1Q36922849-067C9992-0AC7-4F4B-8462-B719B50941AEQ37133999-5EF3CF59-E5A2-495E-883C-B0A921A0B3CAQ37216891-23E11047-5AD5-4BDC-89E1-5378BB497F40Q37339987-0430390E-FE82-4DA8-931E-F60A82A2FF36Q37531676-3A85EB28-FE83-420F-B5D3-AB534F36A85FQ37733168-33566B84-B059-48B6-BB89-41F082854412Q37918720-0A9FC6A5-4EDC-4109-A1F5-400D6A31F868Q38099065-A828E003-1461-4D53-B025-9B432D9E9944Q38212812-7C1566A4-6243-41D1-B716-E7844B2DD644Q38214677-51464650-9709-4F93-8E7E-D5E391750C5CQ38867229-4914EFA4-A6E0-4688-BF5F-FAB47A2CC97EQ39247056-4AB8E36C-285A-4CF9-9A41-EC13E41E6C56Q39413091-5B11883C-DE6F-4DA5-AB38-3306FB4C6FF9Q39627330-30CB97EA-63B0-4C87-A13E-7F27559229A1Q39927199-6D0FF677-73C1-41D7-A59E-1827434466EDQ42150849-BFE47CDF-513D-4319-92E2-8F5278059A30Q42278719-C58E33F8-C1E1-488C-9D04-9E0C87ED5360Q42732668-86340F93-DA6A-489D-A3B1-E02D554BCD97Q44216960-C9AB569A-4B36-45AC-981C-EDE84D642A48Q46624207-8CD4F881-421D-448C-A855-F3B39E859474Q47896160-03E6118C-8AD8-4A1F-81C7-4A261CF6EB0EQ48032318-EB1086B1-FA84-4200-809B-B37A3825D1C8Q48205241-5C823FDC-A4B1-44B9-AC32-B21FC7F14E6BQ48275761-1DB26031-0164-46FB-92AD-0F23C0D67E3FQ48501081-B29B2E45-BB40-4441-88DB-2153665FC26DQ48650516-FFEFBF7D-FE5B-479B-999F-F9E39FA2CDB4
P2860
FUS-immunoreactive intranuclear inclusions in neurodegenerative disease.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
FUS-immunoreactive intranuclear inclusions in neurodegenerative disease.
@en
FUS-immunoreactive intranuclear inclusions in neurodegenerative disease.
@nl
type
label
FUS-immunoreactive intranuclear inclusions in neurodegenerative disease.
@en
FUS-immunoreactive intranuclear inclusions in neurodegenerative disease.
@nl
prefLabel
FUS-immunoreactive intranuclear inclusions in neurodegenerative disease.
@en
FUS-immunoreactive intranuclear inclusions in neurodegenerative disease.
@nl
P1433
P1476
FUS-immunoreactive intranuclear inclusions in neurodegenerative disease
@en
P2093
Ian R A Mackenzie
John Woulfe
P2860
P304
P356
10.1111/J.1750-3639.2009.00337.X
P577
2009-09-21T00:00:00Z